Rare disease specialist BioMarin has agreed to acquire Prosensa and its Duchenne muscular dystrophy (DMD) candidate drisapersen in a deal valued at up to around $840 million.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback